GlassScriptPhysician profile
Cullen Ocmond
NPI 1053588467
$3,522.90
in general payments reported to CMS, 2019-2025
33 companies · $854 in 2025
The $854 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $417 · 2021: $407 · 2022: $347 · 2023: $562 · 2024: $521 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,918 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,918.15 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.13 | 2021-2025 | |
| Amgen INC. | $397.20 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $359.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $325.64 | 2019-2025 | Gardasil 9, Capvaxive, Belsomra |
| Novo Nordisk INC | $310.24 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Abbott Laboratories | $145.68 | 2022-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $142.05 | 2019-2021 | |
| Axsome Therapeutics, INC. | $108.43 | 2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $103.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.35 | 2022-2025 | Jardiance |
| Vanda Pharmaceuticals INC. | $84.71 | 2025 | Fanapt |
| Pfizer INC. | $78.44 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $73.19 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $72.25 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $54.24 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $38.04 | 2022-2024 | Airsupra |
| Ironwood Pharmaceuticals, INC | $34.28 | 2020-2024 | |
| Allergan, INC. | $31.50 | 2019 | |
| Inspire Medical Systems, INC. | $28.60 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $26.78 | 2023 | Quviviq |
| Almatica Pharma LLC | $20.85 | 2025 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $20.36 | 2024 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $19.40 | 2022 | |
| Mayne Pharma Commercial LLC | $19.14 | 2025 | |
| Smith+Nephew, INC. | $18.53 | 2024 | Collagenase Santyl |
| Vertex Pharmaceuticals Incorporated | $18.38 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $16.55 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.86 | 2019 | |
| Astellas Pharma US INC | $15.45 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $14.81 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.14 | 2024 | Caplyta |
| Sanofi-Aventis U.S. LLC | $14.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cullen Ocmond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.